India pharma and healthcare deal volumes rise 23% in Q3 2026
In short
India’s pharma and healthcare sector had 87 deals worth $4.3 billion in Q3 2026. The report said private equity activity picked up and public market fundraising also improved.
This matters because it shows more money moving into the sector. The report does not name the biggest deals or say which companies raised funds.
What the reporting says
India’s pharma and healthcare sector recorded 87 deals worth $4.3 billion in Q3 2026, according to the report. The publisher summary said private equity activity surged and public market fundraising gained momentum, pointing to stronger transaction activity in the sector. The report did not identify the largest deals, the companies involved, or whether the pace will continue.
Why it matters
India’s pharma and healthcare sector posted 87 deals worth $4.3 billion in Q3 2026, with private equity activity and public market fundraising both rising, according to the report. The summary points to stronger capital flows and deal-making momentum. It does not name the companies, transactions, or financing route details, so the sources do not show which segment drove most of the value.